Incannex’s IHL-42X Shows Promising Results in Obstructive Sleep Apnea Treatment

Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc., highlighting continued progress in the clinical development of IHL-42X for obstructive sleep apnea. The update follows the release of full Phase 2 RePOSA data and exit-interview analyses, which showed both low and high-dose IHL-42X achieved statistically significant reductions in Apnea-Hypopnoea Index compared to placebo. The high-dose arm demonstrated maximum AHI reductions of up to 83%, indicating substantial improvement in sleep apnea severity.

Patient-reported outcomes from exit interviews revealed that 57.6% of participants reported perceived improvement in their OSA condition, with most describing the change as meaningful to their daily lives. This combination of objective clinical measures and subjective patient experience strengthens the evidence base for IHL-42X’s potential effectiveness. The treatment was well tolerated across both dose cohorts, suggesting a favorable safety profile that could support broad use if approved.

The development program benefits from regulatory support, as IHL-42X has received fast track designation from the FDA, which can expedite the review process for drugs addressing serious conditions with unmet medical needs. Incannex reported $68.9 million in cash and cash equivalents, providing financial resources to advance clinical programs. Additional positive Phase 2 results were noted for PSX-001, another candidate in the company’s pipeline. For detailed information including downloadable images and additional materials, visit https://www.stonegateinc.com.

These developments matter because obstructive sleep apnea affects millions worldwide and is associated with serious health risks including cardiovascular disease, stroke, and daytime impairment. Current treatments often involve cumbersome devices like CPAP machines or invasive surgical options, creating a significant need for effective pharmaceutical alternatives. The combination of strong clinical data, patient-reported benefits, regulatory fast track status, and financial stability positions Incannex to potentially address this substantial medical need. The progress in OSA treatment could have broader implications for sleep medicine and related health outcomes.

This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Incannex’s IHL-42X Shows Promising Results in Obstructive Sleep Apnea Treatment.

The post Incannex’s IHL-42X Shows Promising Results in Obstructive Sleep Apnea Treatment appeared first on citybuzz.